B Cell Lymphoma
From the Journals
RIT consolidation may be an option for unfit MCL patients
Patients who could not undergo transplants had high rates of complete responses to radioimmunotherapy consolidation following induction...
From the Journals
Bendamustine/rituximab combo proves viable for comorbid CLL
Combination bendamustine and rituximab offers an effective treatment option for older, sicker patients with chronic lymphocytic leukemia.
From the Journals
In situ vaccination produced responses in indolent NHL
In situ vaccination induced regression of tumors that were directly targeted, as well as tumors that were not treated, in a small study of...
From the Journals
DA-EPOCH-R appears more toxic than standard R-CHOP in DLBCL
The National Clinical Trials Network is seeking to identify molecular subsets to see if specific chemotherapy platforms or targeted agents can...
Latest News
Polatuzumab outperforms pinatuzumab in non-Hodgkin lymphoma
Polatuzumab vedotin plus rituximab produced more durable responses than did pinatuzumab vedotin plus rituximab in patients with relapsed or...
Conference Coverage
Early data support R-BAC for post-BTKi mantle cell lymphoma
GLASGOW – The combination outperformed previously published data for other treatments in the relapsed/refractory setting.
From the Journals
Ibrutinib sustained responses in refractory CLL in long-term follow-up
Follow-up data from the RESONATE study suggests that long-term treatment with ibrutinib is effective and safe in patients with relapsed/refractory...
From the Journals
Rituximab boosts survival in primary CNS lymphoma
The triplet combination of rituximab plus combination high-dose methotrexate and temozolomide could be a safe and effective first-line option for...
From the Journals
High survival in relapsed FL after primary radiotherapy
The study supports the role of primary radiotherapy in the treatment of early-stage follicular lymphoma. But researchers found that patients who...
From the Journals
MCL survival rates improve with novel agents
Median overall survival for mantle cell patients was between 52 and 57 months in two cancer registries. The researchers pointed to the impact of...
From the Journals
Worse survival seen among black patients with MCL
There was a survival gap between black and white patients, even though black patients with mantle cell lymphoma were more likely to be treated in...